About
The PCaReview: Precision in Progress delivers monthly, curated, research-driven insights into the evolving field of prostate cancer care.
This publication provides an overview of current advances, clinical guidelines, and personalized strategies for the diagnosis, treatment, and management of prostate cancer.
Designed for patients, survivors, caregivers, advocates, and healthcare professionals, PCaReview seeks to bridge the gap between scientific discovery and practical understanding. Our goal is to empower readers with evidence-based information that supports informed conversations and thoughtful healthcare decisions.
© 2026 All Rights Reserved
All content in this publication is protected under copyright law. No part of this magazine may be reproduced, distributed, or transmitted in any form without prior written permission from the publisher, except for brief quotations used in reviews or commentary.
Editor-in-Chief: Jacques Pierre
Edition: May 2026
Contributor Notice
Unless otherwise stated, all articles, photographs, illustrations, graphics, and visual materials are the property of their respective creators and are used in this publication under license or agreement.
Trademarks
All brand names, trademarks, logos, and service marks are the property of their respective owners.
Table of Contents
About PCaReview
Evidence Based Guidelines
Advances in Detection and Imaging
- Personalized Risk Stratification and Genetic Testing
- Advanced Therapies and Clinical Trial Opportunities
- Disparities and Population-Specific Risks
Resources and Emerging Diagnostic Tools
Future Directions in Personalized Care
The Top 10 Questions Every Patient Should Ask
Conclusion
Evidence Based Guidelines
Prostate cancer care continues to evolve rapidly. Advances in screening, imaging, genetics, targeted therapy, and precision medicine are reshaping how prostate cancer is diagnosed, monitored, and treated.
Major organizations such as the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Cancer Society (ACS), and National Cancer Institute (NCI) regularly update recommendations to reflect new scientific evidence.
The overall trend in modern prostate cancer care is personalization—matching screening, monitoring, and treatment strategies to an individual's risk profile, genetics, disease stage, and personal goals.
Advances in Detection and Imaging
Historically, prostate cancer detection relied heavily on PSA testing and systematic biopsy techniques. While these methods remain important, they have limitations. Some aggressive cancers may be missed, while other slow-growing cancers may be detected and treated unnecessarily.
Today, physicians have access to more advanced tools that improve accuracy and help reduce overtreatment.
Multiparametric MRI
Multiparametric MRI (mpMRI) allows doctors to identify suspicious areas within the prostate before biopsy. This helps guide targeted biopsies and may reduce the need for unnecessary procedures.
MRI-Targeted Biopsies
Rather than collecting tissue samples randomly, MRI-targeted biopsies focus directly on areas that appear suspicious on imaging, improving diagnostic accuracy.
PSMA PET Imaging
PSMA PET scans represent one of the most significant advances in prostate cancer imaging. These scans can identify prostate cancer cells throughout the body with greater sensitivity than many traditional imaging techniques, particularly in higher-risk and recurrent disease.
Urine-Based Biomarkers
Several urine-based diagnostic tests are being used to help estimate cancer risk and determine whether a biopsy is necessary. These tools may help reduce invasive procedures for some patients.
What This Means for You
Testing is becoming more personalized. Instead of relying solely on a single PSA value, doctors can use multiple tools to better understand your risk and tailor recommendations accordingly.
What to Ask Your Doctor
- How has my PSA changed over time?
- Would an MRI before biopsy be appropriate?
- Is MRI-targeted biopsy available?
- Am I a candidate for PSMA PET imaging?
- Could a urine biomarker test help avoid biopsy?
Learn More
https://www.cancer.gov/types/prostate/prostate-screening-pdq
https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/tests.html
Personalized Risk Stratification and Genetic Testing
Prostate cancer is increasingly recognized as a diverse disease rather than a single condition.
Modern risk stratification combines:
- PSA levels
- Gleason score
- Grade Group
- MRI findings
- Disease stage
- Genetic information
Active Surveillance
For many men with low-risk prostate cancer, active surveillance offers a safe alternative to immediate treatment. Monitoring may include PSA testing, MRI imaging, and periodic biopsies.
Genetic Testing
Inherited mutations such as BRCA1, BRCA2, ATM, CHEK2, and other homologous recombination repair (HRR) genes may influence prognosis and treatment selection.
Why Genetics Matter
Certain therapies—including PARP inhibitors—may be particularly effective in patients whose tumors contain specific DNA repair mutations.
What This Means for You
Understanding your risk category can help prevent overtreatment while ensuring aggressive disease receives appropriate intervention.
What to Ask Your Doctor
- What risk category am I in?
- Is active surveillance appropriate?
- Should I undergo genetic testing?
- Would genetic results affect treatment options?
- Should my family members consider testing?
Learn More
https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq
https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
Advanced Therapies and Clinical Trial Opportunities
Treatment options for advanced prostate cancer continue to expand.
PSMA Radioligand Therapy
Lutetium-177 PSMA-617 delivers radiation directly to prostate cancer cells expressing PSMA while minimizing exposure to surrounding tissue.
PARP Inhibitors
Patients with BRCA or HRR mutations may benefit from PARP inhibitors, which exploit weaknesses in tumor DNA repair mechanisms.
Immunotherapy
Although only effective for select patients, immunotherapy remains an active area of investigation and offers important options in certain clinical situations.
Clinical Trials
Clinical trials remain the driving force behind innovation in prostate cancer care. Many newer therapies were first made available through clinical research studies.
What This Means for You
Patients with advanced disease may have more treatment options than ever before, including therapies specifically designed to target the biology of their cancer.
What to Ask Your Doctor
- Am I eligible for PSMA-targeted therapy?
- Should I undergo additional genetic testing?
- Are PARP inhibitors appropriate?
- What clinical trials are available?
- Would immunotherapy be relevant in my case?
Learn More
https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
Disparities and Population-Specific Risks
Not all populations experience prostate cancer equally.
Black men face significantly higher rates of diagnosis, aggressive disease, and mortality compared with many other groups.
Researchers believe multiple factors contribute:
- Genetics
- Access to healthcare
- Screening disparities
- Delayed diagnosis
- Social determinants of health
Family History Matters
Men with a father, brother, or multiple family members diagnosed with prostate cancer may also have elevated risk.
What This Means for You
Understanding your individual risk profile can help guide earlier detection strategies and more personalized care.
What to Ask Your Doctor
- Am I considered high risk?
- Should screening begin earlier?
- How often should I be screened?
- Are additional tests appropriate?
- Would genetic counseling be helpful?
Learn More
https://prostatehealtheducationnetwork.org
https://www.cancer.gov/about-cancer/understanding/disparities
Resources and Emerging Diagnostic Tools
Emerging technologies are transforming prostate cancer management.
Current areas of innovation include:
- MRI-guided diagnosis
- PSMA PET imaging
- Urine biomarkers
- Liquid biopsies
- Molecular profiling
- Shared decision-making tools
- Risk calculators
- Artificial intelligence-assisted imaging
These tools may improve early detection, monitoring, and treatment selection while reducing unnecessary procedures.
What This Means for You
Modern prostate cancer care increasingly relies on multiple sources of information rather than a single test result.
Learn More
https://www.cancer.net/cancer-types/prostate-cancer
https://www.cancer.org/cancer/prostate-cancer.html
https://www.mayoclinic.org/diseases-conditions/prostate-cancer
https://www.hopkinsmedicine.org/brady-urology-institute/conditions-and-treatments/prostate-cancer
Future Directions in Personalized Care
The future of prostate cancer care lies in precision medicine.
Researchers increasingly use:
- Genomic testing
- Tumor profiling
- Molecular biomarkers
- Artificial intelligence
- Liquid biopsy technology
- Advanced imaging
- Targeted therapies
Genomic Classifiers
Tests such as Decipher help estimate recurrence risk and guide treatment intensity.
Precision Medicine
Treatment decisions are increasingly based on the biology of an individual's cancer rather than broad population averages.
What This Means for You
Personalized care may improve outcomes while reducing unnecessary treatment and side effects.
Learn More
https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
The Top 10 Questions Every Patient Should Ask
- What exact risk category am I in?
- Should I undergo genetic testing?
- Am I eligible for clinical trials?
- Are we following current NCCN or ASCO guidelines?
- Would MRI or PSMA PET imaging change my treatment plan?
- Is active surveillance appropriate for me?
- Are there urine-based tests that may help avoid biopsy?
- What does my genetic profile mean for treatment?
- Should I seek a second opinion?
- How often should I be monitored based on my risk?
Conclusion
The more informed and prepared you are, the more productive your conversations with your healthcare team can be.
Prostate cancer care continues to evolve through advances in imaging, genetics, precision medicine, and targeted therapies. While every patient’s journey is unique, understanding the latest evidence-based recommendations can help you make informed decisions and participate actively in your care.
Before your next appointment:
- Write down your questions.
- Review your family history.
- Bring recent test results.
- Discuss whether additional testing is appropriate.
- Ask about new technologies or clinical trial opportunities that may be relevant to your situation.
Knowledge empowers better conversations, better decisions, and better care.
Medical Disclaimer
This publication is intended for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Readers should consult qualified healthcare professionals regarding individual medical decisions, treatment options, and healthcare concerns.